Investment Information

With transparent disclosure of information and communication with markets,
we will grow along with shareholders.

Hanall Biopharma, Achieving Net Income of 540M KRW to Turn into Surplus

Date|2014-05-23

Related Data |[보도]2014.05.23(1분기 흑자전환).docx파일 다운로드
Hanall Biopharma, Achieving Net Income of 540M KRW to Turn into Surplus​


On 23rd, Hanall Biopharma has announced that the company has gained 19.9 billion KRW of sales, 48 million KRW of operating profit, and 540 million KRW of net income in this first quarter. As the company has gained 17.9 billion KRW of sales, 1.78 billion KRW of operating loss, and 1.98 billion KRW of net loss in the first quarter of 2013, the sales has increased by 11.2% from the last first quarter, and the operating profit and the net profit have turned around into surplus.​


One of the staffs has mentioned, “The Company has shown a huge loss in the last year due to expansion of R&D expenses and TV commercial expenses for functional shampoo Alpecin and Plantur. However, the expansion of sales of strategic products will bring growth of sales and profit, and the Company is aiming for the turnaround of whole year.”​


  

NextHanall Completed the CGMP-class Production Plant for Cutting-edge Solid Formula

PrevHanall Biopharma, Completed the Clinical Trial Phase 1 of “HL036,” New Medicine for Dry Eye Disease

List